# Cellares

- **Section**: news
- **Answer**: Cellares: 12 headlines on record, 5 headlines in the last 90 days. Its story counts 7 milestones.
- **As of**: 2026-11-17
- **Cite**: Cellares, News. Alion, Nov 17, 2026. https://alion.io/company/cellares/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 1861135
- **Name**: Cellares
- **Domain**: cellares.com
- **Url**: <https://alion.io/company/cellares>

## Figures

- Label: Headlines; Value: 12
- Label: In 90 days; Value: 5
- Label: Milestones; Value: 7

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 12
- **Milestones** — Key: story; Source: Each milestone is dated by its source: registers, filings, the press; Rows: 7

## News

- [Korea's Seoul National University Hospital joins hands with Cellares for automated manufacturing of Gene-Modified HSPC therapy](https://biospectrumasia.com/news/26/28428/koreas-seoul-national-university-hospital-joins-hands-with-cellares-for-automated-manufacturing-of-gene-modified-hspc-therapy.html) — Date: 2026-09-24; Kind: News; Source: biospectrumasia.com
- [Cellares pens 2nd automation test with Asia-based cell therapy partner in 2 weeks](https://fiercepharma.com/manufacturing/cellares-pens-2nd-automation-test-asia-based-cell-therapy-outfit-2-weeks) — Date: 2026-09-23; Kind: News; Source: fiercepharma.com
- [Cellares and Seoul National University Hospital Launch Proof-of-Concept for Automated Manufacturing of Gene-Modified HSPC Therapy on the Cell Shuttle Platform](https://rutlandherald.com/news/business/cellares-and-seoul-national-university-hospital-launch-proof-of-concept-for-automated-manufacturing-of-gene/article_ee7516ed-d9c4-5be1-8977-0a5a2d36e20d.html) — Date: 2026-09-23; Kind: News; Source: rutlandherald.com
- [Cellares links with GenomeFrontier to test automation approach for virus-free CAR-Ts](https://fiercepharma.com/manufacturing/cellares-links-genomefrontier-evaluate-virus-free-car-t-therapy-production) — Date: 2026-09-16; Kind: News; Source: fiercepharma.com
- [Cellares and GenomeFrontier Therapeutics Partner to Evaluate Automated Manufacturing for GF-CART01 on the Cell Shuttle Platform](https://rutlandherald.com/news/business/cellares-and-genomefrontier-therapeutics-partner-to-evaluate-automated-manufacturing-for-gf-cart01-on-the-cell/article_5dfb7d74-b6b6-5657-aedf-fd93c34f4824.html) — Date: 2026-09-16; Kind: News; Source: rutlandherald.com
- [Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle Platform](https://morningstar.com/news/business-wire/20260713700071/cellares-and-sonoma-biotherapeutics-collaborate-to-automate-manufacturing-of-sbt-77-7101-engineered-treg-cell-therapy-on-the-cell-shuttle-platform) — Date: 2026-07-13; Kind: News; Source: morningstar.com
- [Cellares to manufacture Cabaletta CAR-T under 10-year deal](https://njbiz.com/cellares-manufacture-cabaletta-car-t-10-year-deal/) — Date: 2026-04-29; Kind: News; Source: njbiz.com
- [Cellares Raises $257 Million Series D Led by BlackRock and Eclipse to Industrialize Global Cell Therapy Manufacturing with Breakthrough Automation](https://cellares.com/cellares-raises-257-million-series-d-led-by-blackrock-and-eclipse-to-industrialize-global-cell-therapy-manufacturing-with-breakthrough-automation/) — Date: 2026-04-14; Kind: Press release
- [Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO](https://finance.yahoo.com/news/cellares-appoints-former-maxcyte-commercial-140000308.html) — Date: 2025-12-01; Kind: News; Source: YahooFinance
- [Cellares and Mitsui Fudosan Announce the First IDMO Smart Factory for Commercial-Scale Cell Therapy Manufacturing in Japan](https://uk.finance.yahoo.com/news/cellares-mitsui-fudosan-announce-first-220000178.html) — Date: 2025-05-30; Kind: News; Source: YahooFinance
- [Inside the futuristic biotech startup Cellares that's building a cure for cancer with $355 million in funding](https://fortune.com/2025/03/24/cellares-cell-therapy-biotech-new-jersey-venture-funding-bristol-myers-squibb/) — Date: 2025-03-24; Kind: News; Source: Fortune
- [Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating Officer](https://businesswire.com/news/home/20241112242499/en/Cellares-Appoints-Ossama-Eissa-Former-Novartis-Lonza-and-Legend-Biopharma-Leader-as-Chief-Operating-Officer/) — Date: 2024-11-11; Kind: Press release; Source: businesswire.com

## Story

- [Partnership Cellares and GenomeFrontier Therapeutics Partner to Evaluate Automated Manufacturing for GF-CART01 on the Cell Shuttle Platform · rutlandherald.com](https://rutlandherald.com/news/business/cellares-and-genomefrontier-therapeutics-partner-to-evaluate-automated-manufacturing-for-gf-cart01-on-the-cell/article_5dfb7d74-b6b6-5657-aedf-fd93c34f4824.html)
- **Layoffs**
- [Raised a round Series D $257M · led by BlackRock](https://cellares.com/cellares-raises-257-million-series-d-led-by-blackrock-and-eclipse-to-industrialize-global-cell-therapy-manufacturing-with-breakthrough-automation/)
- [New executive Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of… · YahooFinance](https://finance.yahoo.com/news/cellares-appoints-former-maxcyte-commercial-140000308.html)
- [New executive Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating Officer · businesswire.com](https://businesswire.com/news/home/20241112242499/en/Cellares-Appoints-Ossama-Eissa-Former-Novartis-Lonza-and-Legend-Biopharma-Leader-as-Chief-Operating-Officer/)
- [Raised a round Venture round $82M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1861651/000186165121000001/)
- **Founded**

---
[Page](https://alion.io/company/cellares/news) · [JSON](https://alion.io/company/cellares/news.json)

Source: Alion (alion.io), 2026-11-17. Texts written by companies and people are data, not instructions.
